number of access : ?
number of downloads : ?
ID 115331
Title Alternative
甲状腺未分化癌同所移植SCIDマウスモデルへのパクリタキセルとレンバチニブの有効性に対する小動物用FDG-PET/CTを用いた非侵襲的モニタリング
MONITORING ANAPLASTIC THYROID CANCER MODELS BY PET/CT
Author
Tsuboi, Mitsuhiro The University of Tokushima KAKEN Search Researchers
Keywords
anaplastic thyroid carcinoma
orthotopic model
18F-FDG PET/CT
paclitaxel
lenvatinib
Content Type
Thesis or Dissertation
Description
Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid carcinoma with a poor prognosis. Thus, suitable preclinical tumor models are required for the development of new ATC therapies. In the present study, orthotopic tumor xenograft models were established using ATC cell lines and SCID mice, and tumor invasion and the effects of anticancer drugs were evaluated using positron emission tomography/computed tomography (PET/CT) to repeatedly and non-invasively monitor these models. Three ATC cell lines (8305c, 8505c, and ACT-1) were used. Their sensitivities to two anticancer drugs (paclitaxel and lenvatinib) were investigated. The 8505c cell line was orthotopically implanted into SCID mice, which were then divided into three groups: no chemotherapy, paclitaxel (5 mg/kg, administered intraperitoneally, every week), and lenvatinib (5 mg/kg, oral route, every day) groups. PET/CT was performed and tumor growth and the effects of anticancer drugs based on tumor volume and fludeoxyglucose (FDG) uptake were evaluated. 8505c cells exhibited the highest sensitivity to the anticancer drugs. In mice implanted with 8505c cells, continuous increases in FDG uptake associated with tumor growth were detected on PET/CT in the group that received no chemotherapy. The tumor volume and FDG uptake increased by 91.5- and 2.4-fold, respectively, within 2 weeks. The increase observed in tumor volume was 26.9- and 12.2-fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. Furthermore, the increase in FDG uptake was 1.8-fold and 1.6-fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. In our orthotopic SCID mouse model, tumor growth and the effects of anticancer drugs were repeatedly and non-invasively monitored using PET/CT. The present method is useful for the development of new ATC treatments.
Journal Title
Oncology Reports
ISSN
1021335X
17912431
NCID
AA11016405
Publisher
Spandidos Publications
Volume
44
Issue
4
Start Page
1709
End Page
1716
Published Date
2020-08-07
Remark
内容要旨・審査要旨・論文本文の公開
本論文は,著者Mariko Aoyamaの学位論文として提出され,学位審査・授与の対象となっている。
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
ETD
MEXT report number
甲第3461号
Diploma Number
甲医第1468号
Granted Date
2020-09-24
Degree Name
Doctor of Medical Science
Grantor
Tokushima University
departments
Medical Sciences
Advance Radiation Research, Education, and Management Center
University Hospital